Studies
The CTN+ supports clinical trials to find new ways to prevent, treat and manage HIV and other STBBIs, prioritizing a community-based approach of the highest scientific and ethical standards.
-
CTN 115: 141W94 (Amprenavir) versus Indinavir
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Standard Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI-Experienced, Protease Inhibitor (PI)-Naïve, HIV-1 Infected Patients. (Protocol PROA/B3006 [569/050]): Trial results
-
CTN 114: SCH 56592 versus Fluconazole for Thrush
A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results
-
CTN 113: Adding 1592 (Abacavir) versus Adding Indinavir
A Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IND in HIV-1 Infected, Antiretroviral Therapy-Naïve Subjects: Trial results
-
CTN 112: DMP 266 plus Indinavir
A Phase III, Double-Blind, Placebo-Controlled, Multicentre Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy: Trial results
-
CTN 111: DMP 266 (Efavirenz) in Two- or Three-Drug Arm
A Phase III, Multicentre, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Combination Regimens (DMP 266 plus Indinavir, DMP 266 plus Zidovudine plus Lamivudine, Indinavir plus Zidovudine plus Lamivudine) in HIV-Infected Patients
-
CTN 110: Subcutaneous interleukin-2 in the setting of HIV infection
A randomized, open-label, phase III, international study of subcutaneous recombinant IL-2 (Proleukin®) in patients with HIV-1 infection and CD4+ cell counts u0026gt; 300 cells/mm3 (Evaluation of subcutaneous Proleukin in a randomized international trial; ESPRIT): Trial results
-
CTN 102: Nelfinavir versus Ritonavir (NvR)
A Randomized Trial of the Efficacy and Safety of Nelfinavir vs. Ritonavir added to Background Antiretroviral Nucleoside Therapy in HIV-Infected Individuals with CD4+ Cell Counts u0026lt; 100 mm3: Trial results
-
CTN 101: Hydrea in Combination
A randomized study of antiviral activity and safety of combinations of didanosine, stavudine, zidovudine, and/or hydrea in anti-retroviral treatment-naive HIV-infected subjects: Trial results
-
CTN 094: AZT/3TC/Nelfinavir (AVANTI III)
A Randomized, Double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection. (AVANTI-Project 113; Protocol 067C): Trial results
-
CTN 093: Nevirapine/3TC
An International, Double-blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety and Effectiveness of Nevirapine in Preventing Clinical AIDS Progression Events or Death when Used in Combination with 3TC and Stable (4wks) Background Nucleoside Therapy: Trial results
-
CTN 091: Mixed Carotenoids
A Randomized Clinical Trials of Daily Multivitamin with or without Mixed Carotenoid Supplementation in Advanced HIV Disease: Trial results
-
CTN 090: AZT/3TC/Indinavir (AVANTI II)
A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for the Treatment of HIV-1 Infection: Trial results
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.
Learn More